Ergün Y - Search Results

1

Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.

Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ. Gürbüz M, et al. Among authors: ergun y. J Gastrointest Cancer. 2022 Jun;53(2):282-288. doi: 10.1007/s12029-021-00594-1. Epub 2021 Feb 4. J Gastrointest Cancer. 2022. PMID: 33538958

2

Alternative approaches to risk-benefit balancing in immunotherapy.

Ilhan Y, Ergun Y. Ilhan Y, et al. Among authors: ergun y. Lancet Oncol. 2024 May;25(5):e178. doi: 10.1016/S1470-2045(24)00085-8. Lancet Oncol. 2024. PMID: 38697161 No abstract available.

3

Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.

Ergun Y, Ozdemir NY, Guner EK, Esin E, Sendur MA, Koksoy EB, Demirci NS, Eren T, Dede I, Sezer A, Engin H, Oksuzoglu B, Yalcin B, Utkan G, Zengin N, Urun Y. Ergun Y, et al. J BUON. 2018 Dec;23(7):116-121. J BUON. 2018. PMID: 30722120 Free article.

4

Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study.

Ergun Y, Yildirim Ozdemir N, Toptas S, Kurtipek A, Eren T, Yazici O, Sendur MA, Akinci B, Ucar G, Oksuzoglu B, Uncu D. Ergun Y, et al. J BUON. 2019 Jul-Aug;24(4):1719-1726. J BUON. 2019. PMID: 31646831 Free article.

5

KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.

Ergun Y, Acikgoz Y, Bal O, Ucar G, Dirikoc M, Caliskan Yildirim E, Akdeniz N, Uncu D. Ergun Y, et al. Expert Rev Mol Diagn. 2019 Dec;19(12):1131-1140. doi: 10.1080/14737159.2019.1693266. Epub 2019 Nov 19. Expert Rev Mol Diagn. 2019. PMID: 31718325

6

Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?

Ergun Y, Bal O, Dogan M, Uncu D. Ergun Y, et al. J BUON. 2019 Nov-Dec;24(6):2435-2441. J BUON. 2019. PMID: 31983117 Free article.

7

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?

Ergun Y, Bal O, Dogan M, Ucar G, Dirikoc M, Acikgoz Y, Bacaksiz F, Uncu D. Ergun Y, et al. J Res Med Sci. 2020 Feb 20;25:14. doi: 10.4103/jrms.JRMS_1056_18. eCollection 2020. J Res Med Sci. 2020. PMID: 32174986 Free PMC article.

8

The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer.

Ucar G, Ergun Y, Acikgoz Y, Uncu D. Ucar G, et al. Among authors: ergun y. Asia Pac J Clin Oncol. 2020 Oct;16(5):e179-e184. doi: 10.1111/ajco.13328. Epub 2020 Apr 16. Asia Pac J Clin Oncol. 2020. PMID: 32301263

9

The effect of chemotherapy on olfactory function and mucociliary clearance.

Eravcı FC, Uçar G, Özcan KM, Çolak M, Ergün Y, Açıkgöz Y, Ikincioğulları A, Uncu D, Dere HH. Eravcı FC, et al. Among authors: ergun y. Support Care Cancer. 2021 Mar;29(3):1635-1641. doi: 10.1007/s00520-020-05639-y. Epub 2020 Aug 4. Support Care Cancer. 2021. PMID: 32749656

10

The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.

Beypinar I, Demir H, Sakin A, Taskoylu BY, Sakalar T, Ergun Y, Korkmaz M, Ates O, Eren T, Turhal S, Artac M. Beypinar I, et al. Among authors: ergun y. J Gastrointest Cancer. 2021 Sep;52(3):932-939. doi: 10.1007/s12029-020-00514-9. J Gastrointest Cancer. 2021. PMID: 32914373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters